Ilmarinen Mutual Pension Insurance Co Reduces Stock Position in Eli Lilly and Company $LLY

Key Points

• Ilmarinen Mutual Pension Insurance Co trimmed its Eli Lilly stake by 2.0% in the fourth quarter, selling 2,800 shares and leaving it with 135,300 shares worth about $145.4 million.
• Eli Lilly’s latest quarter beat expectations, with EPS of $8.55 and revenue of $19.8 billion, both above analyst estimates, while revenue jumped 55.5% year over year.
• The company remains broadly supported by institutions and analysts: 82.53% of shares are institutionally owned, and brokerages have a consensus rating of Moderate Buy with an average price target of $1,227.

Ilmarinen Mutual Pension Insurance Co trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,300 shares of the company's stock after selling 2,800 shares during the period. Eli Lilly and Company comprises about 1.2% of Ilmarinen Mutual Pension Insurance Co's investment portfolio, making the stock its 13th largest position. Ilmarinen Mutual Pension Insurance Co's holdings in Eli Lilly and Company were worth $145,404,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LLY. Cidel Asset Management Inc. boosted its position in shares of Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after acquiring an additional 5,591 shares during the last quarter. Spire Wealth Management raised its stake in Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after purchasing an additional 592 shares during the period. Coldstream Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock valued at $32,365,000 after purchasing an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Eli Lilly and Company by 30.8% during the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company's stock valued at $33,471,000 after buying an additional 7,338 shares during the period. Finally, Teachers Retirement System of The State of Kentucky grew its stake in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company's stock valued at $126,022,000 after buying an additional 5,595 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

LLY stock opened at $1,126.66 on Friday. The firm has a market cap of $1.06 trillion, a P/E ratio of 40.02, a price-to-earnings-growth ratio of 1.18 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,149.10. The stock has a 50-day simple moving average of $952.15 and a 200-day simple moving average of $1,009.10.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the firm posted $3.34 earnings per share. The business's quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's payout ratio is currently 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark will restore coverage for Zepbound and begin covering Lilly’s new obesity pill Foundayo, meaning all three major U.S. pharmacy benefit managers now cover Lilly’s full obesity portfolio. That broadens access, supports prescription growth, and strengthens Lilly’s position in the fast-growing weight-loss market. Article Title
• Positive Sentiment: Lilly announced three vaccine acquisitions worth up to about $3.8 billion combined, signaling a strategic expansion beyond obesity and diabetes into infectious disease prevention. Investors may view the deal-making as a long-term growth move that diversifies the pipeline. Article Title
• Positive Sentiment: The company also highlighted strong clinical momentum, including new data for Foundayo, Mounjaro, and retatrutide ahead of the ADA conference. The late-stage results suggest Lilly could keep extending its lead in cardiometabolic care. Article Title
• Positive Sentiment: Several firms reiterated bullish views, including BofA raising its price target and Wolfe Research maintaining an Outperform rating. That reinforces the market’s confidence in Lilly’s earnings and pipeline growth. Article Title
• Neutral Sentiment: Lilly presented at Bernstein’s Strategic Decisions Conference and is set to appear at other healthcare conferences, which keeps attention on management’s outlook but is not, by itself, a major fundamental driver. Article Title
• Negative Sentiment: Some commentary warned that Lilly’s valuation is rich and that Novo Nordisk could still be a strong competitor in the obesity-pill market. That may limit upside if investors become more cautious about how much growth is already priced in. Article Title

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on LLY. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a research report on Tuesday, February 10th. The Goldman Sachs Group restated a "buy" rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Wolfe Research restated an "outperform" rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Rothschild & Co Redburn boosted their target price on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Finally, Truist Financial reissued a "buy" rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,227.00.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.